<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cir Dig</journal-id><journal-id journal-id-type="iso-abbrev">Arq Bras Cir Dig</journal-id><journal-id journal-id-type="publisher-id">abcd</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cirurgia Digestiva : ABCD</journal-title></journal-title-group><issn pub-type="ppub">0102-6720</issn><issn pub-type="epub">2317-6326</issn><publisher><publisher-name>Col&#x000e9;gio Brasileiro de Cirurgia Digestiva</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10727144</article-id><article-id pub-id-type="doi">10.1590/0102-672020230068e1786</article-id><article-id pub-id-type="other">00604</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>DEVELOPMENT OF ADENOCARCINOMA AFTER RADIOFREQUENCY ABLATION OF BARRETT&#x02019;S ESOPHAGUS ASSOCIATED TO FUNDOPLICATION AND SUPPRESSION-DUODENAL DIVERSION PROCEDURE: A LESSON TO BE LEARNED</article-title><trans-title-group xml:lang="pt"><trans-title>ADENOCARCINOMA EM ES&#x000d4;FAGO DE BARRETT AP&#x000d3;S ABLA&#x000c7;&#x000c3;O POR RADIOFREQU&#x000ca;NCIA ASSOCIADA A FUNDOPLICATURA E DIVERS&#x000c3;O DUODENAL</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2024-3029</contrib-id><name><surname>Braghetto</surname><given-names>Italo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff1">
<label>1</label>University of Chile, Faculty of Medicine, Department of Surgery, Hospital &#x0201c;Dr. Jos&#x000e9; J. Aguirre&#x0201d;&#x02013; Santiago de Chile, Chile.</aff></contrib-group><author-notes><corresp id="c1">
<bold>Correspondence</bold>: Italo Braguetto. E-mail: <email>italobraghetto@gmail.com</email>
</corresp><fn fn-type="COI-statement"><p>Conflict of interests: None</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>12</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2023</year></pub-date><volume>36</volume><elocation-id>e1786</elocation-id><history><date date-type="received"><day>02</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2023</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p></license></permissions><abstract><title>ABSTRACT</title><p>Despite endoscopic eradication therapy being an effective and durable treatment for Barrett&#x02019;s esophagus-related neoplasia, even after achieving initial successful eradication, these patients remain at risk of recurrence and require ongoing routine examinations. Failure of radiofrequency ablation and argon plasma coagulation is reported in 10&#x02013;20% of cases.</p></abstract><trans-abstract xml:lang="pt"><title>RESUMO</title><p>Apesar de a terapia de erradica&#x000e7;&#x000e3;o endosc&#x000f3;pica ser um tratamento eficaz e dur&#x000e1;vel para a neoplasia relacionada ao es&#x000f4;fago de Barrett (BE), mesmo ap&#x000f3;s a erradica&#x000e7;&#x000e3;o inicial bem-sucedida, esses pacientes permanecem em risco de recorr&#x000ea;ncia e requerem exames de rotina cont&#x000ed;nuos. A falha na abla&#x000e7;&#x000e3;o por radiofrequ&#x000ea;ncia e na coagula&#x000e7;&#x000e3;o com plasma de arg&#x000f4;nio &#x000e9; relatada em 10&#x02013;20% dos casos.</p></trans-abstract><kwd-group><title>HEADGINGS:</title><kwd>Barrett Esophagus</kwd><kwd>Endoscopy</kwd><kwd>Radiofrequency Ablation</kwd><kwd>Argon Plasma Coagulation</kwd><kwd>Fundoplication</kwd><kwd>Gastrectomy</kwd></kwd-group><kwd-group xml:lang="pt"><title>DESCRITORES:</title><kwd>Es&#x000f4;fago de Barrett</kwd><kwd>Endoscopia</kwd><kwd>Abla&#x000e7;&#x000e3;o por Radiofrequ&#x000ea;ncia</kwd><kwd>Coagula&#x000e7;&#x000e3;o com Plasma de Arg&#x000f4;nio</kwd><kwd>Fundoplicatura</kwd><kwd>Gastrectomia</kwd></kwd-group><counts><fig-count count="0"/><table-count count="1"/><equation-count count="0"/><ref-count count="11"/></counts></article-meta></front><body><p>Recently, it was published the paper &#x0201c;Suppression-duodenal diversion procedure for long-segment Barrett&#x000b4;s esophagus: early and long-term outcome&#x0201d;<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>. During the postoperative follow-up, eradication of dysplasia was obtained, as shown in Table 5 of this paper. However, in one patient initially presenting low grade dysplasia, after 5 years of follow-up, the presence of adenocarcinoma at distal esophagus was confirmed histologically, probably remaining buried cells (<xref rid="t1" ref-type="table">Table 1</xref>)<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>. The complete assessment included computed tomography (CT) scan, positron emission tomography (PET) scan, and endo-sonography, affirming a T1b esophageal adenocarcinoma. The definitive treatment indicated for this patient was esophagectomy with colon interposition.</p><table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Histologic results after treatment with argon plasma coagulation or radiofrequency ablation in patients with intestinal metaplasia alone or with dysplasia. The results were observed during follow-up<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>.</title></caption><table frame="hsides" rules="groups"><colgroup width="24%" span="1"><col width="1%" span="1"/><col width="1%" span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#D0907B;"><th align="left" colspan="3" rowspan="2" valign="middle"/><th align="center" style="border-bottom: thin solid; border-color: #000000" valign="middle" rowspan="1" colspan="1">APC</th><th align="center" style="border-bottom: thin solid; border-color: #000000" valign="middle" rowspan="1" colspan="1">RFA</th><th align="center" rowspan="2" valign="middle" colspan="1">p-value</th></tr><tr style="background-color:#D0907B;"><th align="center" valign="middle" rowspan="1" colspan="1">n=21 (%)</th><th align="center" valign="middle" rowspan="1" colspan="1">n=31 (%)</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr style="background-color:#E8C8BC;"><td align="left" colspan="6" valign="middle" rowspan="1">Intestinal metaplasia</td></tr><tr style="background-color:#F6E9E4;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" colspan="2" valign="middle" rowspan="1">Before treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (95.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">25(80.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.21</td></tr><tr style="background-color:#E8C8BC;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" colspan="5" valign="middle" rowspan="1">After treatment</td></tr><tr style="background-color:#F6E9E4;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Total initial eradication</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (66.6)<xref rid="TFN1" ref-type="table-fn">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (54.8)<xref rid="TFN1" ref-type="table-fn">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.02</td></tr><tr style="background-color:#E8C8BC;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Residual island</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (28.6)<xref rid="TFN2" ref-type="table-fn">&#x02020;</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (25.8)<xref rid="TFN2" ref-type="table-fn">&#x02020;</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.02</td></tr><tr style="background-color:#F6E9E4;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Reappearance during follow-up</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (5)<xref rid="TFN2" ref-type="table-fn">&#x02020;</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (12.9)<xref rid="TFN2" ref-type="table-fn">&#x02020;</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.37</td></tr><tr style="background-color:#E8C8BC;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Progression to LGD</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr style="background-color:#F6E9E4;"><td align="left" colspan="6" valign="middle" rowspan="1">Intestinal metaplasia with LGD</td></tr><tr style="background-color:#E8C8BC;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" colspan="2" valign="middle" rowspan="1">Before treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (4.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (19.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.21</td></tr><tr style="background-color:#F6E9E4;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" colspan="2" valign="middle" rowspan="1">After treatment</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr style="background-color:#E8C8BC;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Total initial eradication</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (100)<xref rid="TFN1" ref-type="table-fn">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (66.6)<xref rid="TFN1" ref-type="table-fn">*</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.37</td></tr><tr style="background-color:#F6E9E4;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Residual island of IM</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2<xref rid="TFN3" ref-type="table-fn">&#x02021;</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td></tr><tr style="background-color:#E8C8BC;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Reappearance IM during follow-up</td><td align="center" valign="middle" rowspan="1" colspan="1">1<xref rid="TFN2" ref-type="table-fn">&#x02020;</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1<xref rid="TFN2" ref-type="table-fn">&#x02020;</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.4</td></tr><tr style="background-color:#F6E9E4;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Reappearance LGD during follow-up</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr style="background-color:#E8C8BC;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Progression to HGD during follow-up</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr style="background-color:#F6E9E4;"><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Progression to adenocarcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1<xref rid="TFN4" ref-type="table-fn">&#x000a7;</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p>Eradication with regression to carditis</p></fn><fn id="TFN2"><label>&#x02020;</label><p>Treated with repeated APC</p></fn><fn id="TFN3"><label>&#x02021;</label><p>Submitted to endoscopic submucosal dissection.</p></fn><fn id="TFN4"><label>&#x000a7;</label><p>Submitted to esophageal resection.</p></fn><fn id="TFN5"><p>APC: argon plasma coagulation; RFA: radiofrequency ablation; LGD: low-grade dysplasia; IM: intestinal metaplasia; HGD: high-grade dysplasia.</p></fn></table-wrap-foot></table-wrap><p>This finding encourages a very close follow-up because the risk of reappearance of dysplasia remains and, therefore, it is important to keep attention to this eventual complication that unfortunately, occurred to our patient.</p><p>Despite the fact that endoscopic eradication therapy is an effective and durable treatment for Barrett&#x02019;s esophagus (BE) related neoplasia, even after achieving initial successful eradication, these patients remain at risk of recurrence and require continuous examinations. Failure of radiofrequency ablation (RFA) and argon plasma coagulation (APC) is reported in 10&#x02013;20% of cases<sup>
<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>
</sup>.</p><p>The incidence rate of BE recurrence, reported by Cotton et al., was 10.8 per 100 person-years (PY) overall (95%CI 7.8&#x02013;15.0); 8.3 per 100-PY among patients with baseline low-grade dysplasia (95%CI 4.9&#x02013;14.0); and 13.5 per 100-PY among patients with baseline high-grade dysplasia (95%CI 8.8&#x02013;20.7)<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>.</p><p>The incidence rate of dysplasia recurrence was 5.2 per 100-PY overall (95%CI 3.3&#x02013;8.2); 3.3 per 100-PY among patients with baseline low-grade dysplasia (95%CI 1.5&#x02013;7.2), and 7.3 per 100-PY among patients with baseline high-grade dysplasia (95%CI 4.2&#x02013;12.5)<sup>
<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>
</sup>.</p><p>For other authors, BE recurrence after ablation can occur in almost one-third of patients with baseline dysplastic disease &#x02014; mostly during the first year after complete eradication of intestinal metaplasia (CEIM)<sup>
<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B9" ref-type="bibr">9</xref>
</sup>.</p><p>Titi et al. reported the development of subsquamous neoplasia in three patients who were treated with RFA for BE (two developed adenocarcinoma and one developed high-grade dysplasia)<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>. Therefore, patients with BE treated with RFA have a risk of developing subsquamous high-grade dysplasia and adenocarcinoma after successful RFA of BE. In other publications, the development of subsquamous high-grade dysplasia and adenocarcinoma after successful RFA of BE has been also reported. A better prognosis was obtained after combining ablation and proton pump inhibitors<sup>
<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B11" ref-type="bibr">11</xref>
</sup>.</p><p>Our idea went even further ahead performing ablation combined with acid suppression-bile diversion surgical procedure. But, a very disappointing experience occurred with this patient previously mentioned. For this reason, follow-up endoscopies every 6 months are a valid alternative, and it is the way to detect early recurrence or progression to dysplastic lesions<sup>
<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B8" ref-type="bibr">8</xref>
</sup>.</p><p>This is a great lesson to keep in mind!</p></body><back><fn-group><fn fn-type="other" id="fn1"><p>Editorial Support: National Council for Scientific and Technological Development (CNPq).</p></fn><fn fn-type="supported-by" id="fn2"><p>Financial source: None</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Braghetto</surname><given-names>I</given-names></name>
<name><surname>Valladares</surname><given-names>H</given-names></name>
<name><surname>Lanzarini</surname><given-names>E</given-names></name>
<name><surname>Musleh</surname><given-names>M</given-names></name>
<name><surname>Csendes</surname><given-names>A</given-names></name>
<name><surname>Figueroa-Giralt</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Endoscopic ablation combined with fundoplication plus acid suppression-duodenal diversion procedure for long segment Barrett&#x000b4;s esophagus: early and long-term outcome</article-title><source>ABCD Arq Bras Cir Dig</source><year>2023</year><volume>36</volume><elocation-id>e1760</elocation-id><pub-id pub-id-type="doi">10.1590/0102-672020230042e1760</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cotton</surname><given-names>CC</given-names></name>
<name><surname>Haidry</surname><given-names>R</given-names></name>
<name><surname>Thrift</surname><given-names>AP</given-names></name>
<name><surname>Lovat</surname><given-names>L</given-names></name>
<name><surname>Shaheen</surname><given-names>NJ</given-names></name>
</person-group><article-title>Development of evidence-based surveillance intervals after radiofrequency ablation of Barrett&#x02019;s esophagus</article-title><source>Gastroenterology</source><year>2018</year><volume>155</volume><issue>2</issue><fpage>316.e6</fpage><lpage>326.e6</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.04.01</pub-id><pub-id pub-id-type="pmid">29655833</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cotton</surname><given-names>CC</given-names></name>
<name><surname>Wolf</surname><given-names>WA</given-names></name>
<name><surname>Overholt</surname><given-names>BF</given-names></name>
<name><surname>Li</surname><given-names>N</given-names></name>
<name><surname>Lightdale</surname><given-names>CJ</given-names></name>
<name><surname>Wolfsen</surname><given-names>HC</given-names></name>
<etal/>
</person-group><article-title>Late recurrence of Barrett&#x02019;s esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial</article-title><source>Gastroenterology</source><year>2017</year><volume>153</volume><issue>3</issue><fpage>681.e2</fpage><lpage>688.e2</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.05.044</pub-id><pub-id pub-id-type="pmid">28579538</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>C</given-names></name>
<name><surname>Kolb</surname><given-names>JM</given-names></name>
</person-group><article-title>Management of post ablative Barrett&#x02019;s esophagus: a review of current practices and look at emerging technologies</article-title><source>Curr Treat Options Gastroenterol</source><year>2023</year><volume>21</volume><issue>2</issue><fpage>125</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1007/s11938-023-00414-4</pub-id><pub-id pub-id-type="pmid">37284351</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>P</given-names></name>
<name><surname>Gordon</surname><given-names>IO</given-names></name>
<name><surname>Thota</surname><given-names>PN</given-names></name>
</person-group><article-title>Post-ablation buried neoplasia in Barrett&#x02019;s esophagus</article-title><source>Scand J Gastroenterol</source><year>2021</year><volume>56</volume><issue>5</issue><fpage>624</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1080/00365521.2021.1896774</pub-id><pub-id pub-id-type="pmid">33764825</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muthusamy</surname><given-names>VR</given-names></name>
<name><surname>Wani</surname><given-names>S</given-names></name>
<name><surname>Gyawali</surname><given-names>CP</given-names></name>
<name><surname>Komanduri</surname><given-names>S</given-names></name>
<collab>CGIT Barrett&#x02019;s Esophagus Consensus Conference Participants</collab>
</person-group><article-title>AGA clinical practice update on new technology and innovation for surveillance and screening in Barrett&#x02019;s esophagus: expert review</article-title><source>Clin Gastroenterol Hepatol</source><year>2022</year><volume>20</volume><issue>12</issue><fpage>2696.e1</fpage><lpage>2706.e1</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2022.06.003</pub-id><pub-id pub-id-type="pmid">35788412</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pech</surname><given-names>O</given-names></name>
<name><surname>Alqahtani</surname><given-names>SA</given-names></name>
</person-group><article-title>Update on endoscopic treatment of Barrett&#x02019;s oesophagus and Barrett&#x02019;s oesophagus-related neoplasia</article-title><source>Ther Adv Gastrointest Endosc</source><year>2020</year><volume>13</volume><comment>2631774520935241. </comment><pub-id pub-id-type="doi">10.1177/2631774520935241</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>P</given-names></name>
<name><surname>Shaheen</surname><given-names>NJ</given-names></name>
<name><surname>Katzka</surname><given-names>D</given-names></name>
<name><surname>Bergman</surname><given-names>JJGHM</given-names></name>
</person-group><article-title>AGA clinical practice update on endoscopic treatment of Barrett&#x02019;s esophagus with dysplasia and/or early cancer: expert review</article-title><source>Gastroenterology</source><year>2020</year><volume>158</volume><issue>3</issue><fpage>760</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.09.051</pub-id><pub-id pub-id-type="pmid">31730766</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>MC</given-names></name>
<name><surname>Kanthasamy</surname><given-names>KA</given-names></name>
<name><surname>Yeh</surname><given-names>AG</given-names></name>
<name><surname>Kil</surname><given-names>D</given-names></name>
<name><surname>Pompeii</surname><given-names>L</given-names></name>
<name><surname>Yu</surname><given-names>X</given-names></name>
<etal/>
</person-group><article-title>Factors associated with recurrence of barrett&#x02019;s esophagus after radiofrequency ablation</article-title><source>Clin Gastroenterol Hepatol</source><year>2019</year><volume>17</volume><issue>1</issue><fpage>65.e5</fpage><lpage>72.e5</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2018.05.042</pub-id><pub-id pub-id-type="pmid">29902646</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Titi</surname><given-names>M</given-names></name>
<name><surname>Overhiser</surname><given-names>A</given-names></name>
<name><surname>Ulusarac</surname><given-names>O</given-names></name>
<name><surname>Falk</surname><given-names>GW</given-names></name>
<name><surname>Chak</surname><given-names>A</given-names></name>
<name><surname>Wang</surname><given-names>K</given-names></name>
<etal/>
</person-group><article-title>Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett&#x02019;s esophagus</article-title><source>Gastroenterology</source><year>2012</year><volume>143</volume><issue>3</issue><fpage>564.e1</fpage><lpage>566.e1</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2012.04.051</pub-id><pub-id pub-id-type="pmid">22561053</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>LS</given-names></name>
<name><surname>Holt</surname><given-names>BA</given-names></name>
<name><surname>Williams</surname><given-names>R</given-names></name>
<name><surname>Norris</surname><given-names>R</given-names></name>
<name><surname>Tsoi</surname><given-names>E</given-names></name>
<name><surname>Cameron</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>Endoscopic features of buried Barrett&#x02019;s mucosa</article-title><source>Gastrointest Endosc</source><year>2021</year><volume>94</volume><issue>1</issue><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2020.12.031</pub-id><pub-id pub-id-type="pmid">33373645</pub-id>
</element-citation></ref></ref-list></back></article>
